Israel Englander Akero Therapeutics, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 74,628 shares of AKRO stock, worth $4.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,628

Previous 169,591 56.0%

Holding current value

$4.21 Million

Previous $3.98 Million 46.18%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $2.04 Million - $2.79 Million	-94,963 Reduced 56.0%	74,628 $2.14 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $11.4 Million - $15.3 Million	-622,984 Reduced 78.6%	169,591 $3.98 Million
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $9.51 Million - $16.7 Million	535,381 Added 208.16%	792,575 $20 Million
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $2.87 Million - $12.7 Million	252,310 Added 5166.05%	257,194 $6.01 Million
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $194,852 - $300,440	-5,282 Reduced 51.96%	4,884 $228,000
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $8.83 Million - $11.9 Million	-236,851 Reduced 95.88%	10,166 $389,000
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $8.26 Million - $13.5 Million	247,017 New	247,017 $13.5 Million
Q2 2022 Aug 15, 2022	BUY	$8.0 - $15.01 $3.64 Million - $6.84 Million	455,525 Added 698.19%	520,769 $4.92 Million
Q1 2022 May 16, 2022	BUY	$12.97 - $22.26 $590,147 - $1.01 Million	45,501 Added 230.47%	65,244 $926,000
Q4 2021 Feb 14, 2022	BUY	$19.87 - $26.24 $392,293 - $518,056	19,743 New	19,743 $418,000
Q2 2021 Aug 16, 2021	SELL	$24.81 - $32.35 $2.12 Million - $2.77 Million	-85,492 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$24.04 - $34.19 $4.3 Million - $6.12 Million	-178,919 Reduced 67.67%	85,492 $2.48 Million
Q4 2020 Feb 16, 2021	BUY	$25.12 - $29.89 $2.72 Million - $3.23 Million	108,097 Added 69.15%	264,411 $6.82 Million
Q3 2020 Nov 16, 2020	BUY	$30.79 - $39.92 $823,601 - $1.07 Million	26,749 Added 20.65%	156,314 $4.81 Million
Q2 2020 Aug 14, 2020	BUY	$19.25 - $26.76 $1.25 Million - $1.74 Million	65,026 Added 100.75%	129,565 $3.23 Million
Q1 2020 May 14, 2020	BUY	$12.8 - $27.05 $826,099 - $1.75 Million	64,539 New	64,539 $1.37 Million
Q4 2019 Feb 14, 2020	SELL	$17.37 - $27.27 $1.28 Million - $2.01 Million	-73,621 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$16.89 - $29.88 $1.59 Million - $2.81 Million	-94,125 Reduced 56.11%	73,621 $1.67 Million
Q2 2019 Aug 15, 2019	SELL	$18.08 - $19.83 $1.41 Million - $1.55 Million	-77,960 Reduced 31.73%	167,746 $3.21 Million
Q2 2019 Aug 14, 2019	BUY	$18.08 - $19.83 $4.44 Million - $4.87 Million	245,706 New	245,706 $5.08 Million

Others Institutions Holding AKRO

# of Institutions

191

Shares Held

74.6M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.62B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account